New PET tracer could reveal how lung cancer responds to immunotherapy
NCT ID NCT06439914
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a special PET imaging agent called [89Zr]Zr-DFO-emapalumab to see if it can detect non-small cell lung cancer lesions and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imaging agent and undergo PET scans before and about 30 days after starting immunotherapy. The goal is to see if this approach can help doctors better monitor treatment effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?